BP can reduce the injuries and apoptosis of liver tissues in NASH models by improving the activity of PPAR-α, which inhibits the levels of SREBP-1c and PNPLA-3. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatohepatitis.